Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lene Ryom

Showing results (81-90 of 102) with videos related to

Pageof 11
Sort By:
Eclinicalmedicine|October 6, 2025
Mortality using raltegravir versus other integrase strand-transfer inhibitors in people with HIV in Europe and Australia: a prospective multicentre studyErich Tusch, Lene Ryom, Christian Hoffmann, et al.
AIDS (London, England)|July 7, 2026
CD4+ cell count trends after common cancers in people with HIV: a multicohort collaborationAlisa Timiryasova, Lauren Greenberg, Pere Domingo, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 13, 2023
Measures of Longitudinal Immune Dysfunction and Risk of AIDS and Non-AIDS Defining Malignancies in Antiretroviral-Treated People With Human Immunodeficiency VirusFrédérique Chammartin, Amanda Mocroft, Alexander Egle, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 8, 2024
Integrase Strand Transfer Inhibitor-Related Changes in Body Mass Index and Risk of Diabetes: A Prospective Study From the RESPOND Cohort ConsortiumDhanushi Rupasinghe, Loveleen Bansi-Matharu, Matthew Law, et al.
The Lancet. HIV|April 15, 2024
Associations between change in BMI and the risk of hypertension and dyslipidaemia in people receiving integrase strand-transfer inhibitors, tenofovir alafenamide, or both compared with other contemporary antiretroviral regimens: a multicentre, prospective observational study from the RESPOND consortium cohortsDathan M Byonanebye, Mark N Polizzotto, Fernando Maltez, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|August 14, 2024
Risk of tuberculosis after initiation of antiretroviral therapy among persons with HIV in EuropeIsik S Johansen, Ashley Roen, Christian Kraef, et al.
Eclinicalmedicine|January 22, 2026
Cancer burden and risk factors among women with HIV: a multi-regional study from the D:A:D and RESPOND cohort collaborationsWin Min Han, Bastian Neesgaard, Michael Knappik, et al.
HIV Medicine|March 2, 2022
Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortiumDathan M Byonanebye, Mark N Polizzotto, Bastian Neesgaard, et al.
AIDS (London, England)|December 11, 2023
Heavy antiretroviral exposure and exhausted/limited antiretroviral options: predictors and clinical outcomesAmanda Mocroft, Annegret Pelchen-Matthews, Jennifer Hoy, et al.
Cancers|December 30, 2025
Mortality and Non-Fatal Clinical Outcomes After the Most Common Cancers in People with HIV: A Multicohort CollaborationAlisa Timiryasova, Lauren Greenberg, Pere Domingo, et al.
Pageof 11

Showing results (81-90 of 102) with videos related to

Sort By:
Pageof 11
Eclinicalmedicine|October 6, 2025
Mortality using raltegravir versus other integrase strand-transfer inhibitors in people with HIV in Europe and Australia: a prospective multicentre studyErich Tusch, Lene Ryom, Christian Hoffmann, et al.
AIDS (London, England)|July 7, 2026
CD4+ cell count trends after common cancers in people with HIV: a multicohort collaborationAlisa Timiryasova, Lauren Greenberg, Pere Domingo, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 13, 2023
Measures of Longitudinal Immune Dysfunction and Risk of AIDS and Non-AIDS Defining Malignancies in Antiretroviral-Treated People With Human Immunodeficiency VirusFrédérique Chammartin, Amanda Mocroft, Alexander Egle, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 8, 2024
Integrase Strand Transfer Inhibitor-Related Changes in Body Mass Index and Risk of Diabetes: A Prospective Study From the RESPOND Cohort ConsortiumDhanushi Rupasinghe, Loveleen Bansi-Matharu, Matthew Law, et al.
The Lancet. HIV|April 15, 2024
Associations between change in BMI and the risk of hypertension and dyslipidaemia in people receiving integrase strand-transfer inhibitors, tenofovir alafenamide, or both compared with other contemporary antiretroviral regimens: a multicentre, prospective observational study from the RESPOND consortium cohortsDathan M Byonanebye, Mark N Polizzotto, Fernando Maltez, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|August 14, 2024
Risk of tuberculosis after initiation of antiretroviral therapy among persons with HIV in EuropeIsik S Johansen, Ashley Roen, Christian Kraef, et al.
Eclinicalmedicine|January 22, 2026
Cancer burden and risk factors among women with HIV: a multi-regional study from the D:A:D and RESPOND cohort collaborationsWin Min Han, Bastian Neesgaard, Michael Knappik, et al.
HIV Medicine|March 2, 2022
Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortiumDathan M Byonanebye, Mark N Polizzotto, Bastian Neesgaard, et al.
AIDS (London, England)|December 11, 2023
Heavy antiretroviral exposure and exhausted/limited antiretroviral options: predictors and clinical outcomesAmanda Mocroft, Annegret Pelchen-Matthews, Jennifer Hoy, et al.
Cancers|December 30, 2025
Mortality and Non-Fatal Clinical Outcomes After the Most Common Cancers in People with HIV: A Multicohort CollaborationAlisa Timiryasova, Lauren Greenberg, Pere Domingo, et al.
Pageof 11